Viemed Healthcare, a provider of home-based respiratory therapy, outlined its growth strategy at the Midwest IDEAS Conference, projecting low-20% revenue growth in 2026 with approximately $317 million in revenue and $66 million in EBITDA. The company sees a large untapped market: only about 60,000 beneficiaries currently receive its ventilation therapy, versus an estimated 1.25 million Medicare-eligible potential patients. CEO Casey Hoyt noted that complex respiratory services account for roughly half of the business, serving more than 198,000 patients nationwide. Growth is supported by expanding sleep-resupply and maternal-health segments, though these lower-margin lines may pressure EBITDA margins. Viemed has completed three acquisitions in three years, including Lehan's for roughly $28 million to $30 million, and maintains a debt-free balance sheet with leverage expected to stay below two times EBITDA for any major deal.
Viemed Healthcare IncCompany projects low-20% revenue growth driven by large untapped market of 1.25 million Medicare-eligible patients versus 60,000 currently served.
